Revenue (Annual)

Revenue: The sum of all revenue fields included for a company's operating activities.

China SXT Pharmaceuticals, Inc. (SXTC) had Revenue of $1.93M for the most recently reported fiscal year, ending 2024-03-31.

Quarterly Annual

Figures for fiscal year ending 2024-03-31

Income Statement Financials
Revenue	$1.93M
Net Income	$-3.10M
Cost of Goods Sold	$1.37M
Gross Profit	$0.55M
Operating Expenses	$4.44M
Operating Income	$-2.52M
Non-Operating Income/Expense	$-0.58M
Pre-Tax Income	$-3.10M
Normalized Pre-Tax Income	$-3.10M
Income after Taxes	$-3.10M
Income from Continuous Operations	$-3.10M
Consolidated Net Income/Loss	$-3.10M
Normalized Income after Taxes	$-3.10M
EBIT	$-2.52M
EBITDA	$-2.31M
Weighted-Average Shares Outstanding (Basic)	0.11M
Weighted-Average Shares Outstanding (Diluted)	0.11M
Earnings per Share (EPS) (Basic)	$-28.58
Earnings per Share (EPS) (Diluted)	$-28.58
Balance Sheet Financials
Current Assets	$14.23M
Property, Plant, and Equipment	$0.33M
Long-Term Assets	$8.89M
Total Assets	$23.13M
Current Liabilities	$8.90M
Long-Term Debt	$0.12M
Long-Term Liabilities	$0.29M
Total Liabilities	$9.20M
Common Equity	$13.93M
Tangible Shareholders Equity	$13.91M
Shareholders Equity	$13.93M
Common Shares Outstanding	0.28M
Cash Flow Statement Financials
Cash Flow from Operating Activities	$-1.93M
Cash Flow from Investing Activities	$0.03M
Cash Flow from Financial Activities	$-2.62M
Beginning Cash	$17.37M
End Cash	$12.08M
Increase/Decrease in Cash	$-5.29M
Stock-Based Compensation	$0.35M
Common Stock Dividends Paid	--
Preferred Stock Dividends Paid	--
Fundamental Metrics & Ratios
Current Ratio	1.60
Non-Performing Assets / Total Loans	--
Loan Loss Reserves / Non-Performing Loans	--
Debt to Capital Ratio	0.01
Debt to Equity Ratio	0.17
Gross Margin	28.73%
Operating Margin	-130.42%
EBIT Margin	-130.42%
EBITDA Margin	-119.88%
Pre-Tax Profit Margin	-160.67%
Profit Margin	-160.67%
Free Cash Flow	$-1.94M
Loss Ratio	--
Expense Ratio	--
Combined Ratio	--
Asset Turnover	0.08
Inventory Turnover	1.73
Receiveable Turnover	1.47
Days Sales in Receivables	248.84
Return on Equity	-22.24%
Return on Tangible Equity	-22.27%
Return on Assets	-13.40%
Return on Investments	-22.06%
Book Value Per Share	$50.25
Free Cash Flow per Share	$-17.85
Operating Cash Flow per Share	$-17.78

Data from Zacks Investment Research, Inc.